LASSBio-2382 

LASSBio-2382 is a dual ROCK1/ROCK2 inhibitor with ROCK1 IC₅₀ of 0.005 μM and ROCK2 IC₅₀ of 0.003 μM. LASSBio-2382 inhibits viability and migration of cancer cells. LASSBio-2382 can be used for the research of triple-negative breast cancer^[1].

LASSBio-2382 (Compound 17) potently inhibits both purified ROCK1 (IC₅₀ = 0.005 μM) and ROCK2 (IC₅₀ = 0.003 μM) in a cell-free biochemical assay^[1].
LASSBio-2382 is insoluble in the PAMPA-BBB assay, precluding measurement of its blood-brain barrier permeability^[1].
LASSBio-2382 (30 μM; 24 h) reduces MDA-MB-231 cell viability by 28.8%^[1].
LASSBio-2382 (0.1-100 μM; 24 h) inhibits MDA-MB-231 cell migration in a dose-dependent manner, with inhibition reducing wound closure to <50% at 10 μM and <25% at 30 μM, and precipitation observed at 100 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

317.34

C₁₈H₁₅N₅O

2487752-24-7

O=C(CC1=CNC2=C1C=CC=C2)N/N=C/C3=CC(C=NN4)=C4C=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Pinheiro P S M, et al. Discovery of N-Acylhydrazone Derivatives as ROCK Inhibitors: A Journey from Virtual Screening and Structure-Based De Novo Design to the Identification of ROCK2 Selective Inhibitors and Beyond[J]. ACS Bio & Med Chem Au, 2026.